SCHEMBL8273588

SCHEMBL8273588

Nc1cc(F)ccc1N1CCC(CNC(=O)[C@H](O)[C@@H](O)C(=O)N2CCNCC2)CC1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ADAM17 P78536 2/20 0.40
▸ EIF4E P06730 1/20 0.38
▸ MKNK1 Q9BUB5 1/20 0.38
▸ MKNK2 Q9HBH9 1/20 0.38
▸ HDAC3 O15379 4/20 0.38
▸ HDAC2 Q92769 4/20 0.38
▸ HDAC1 Q13547 3/20 0.38
▸ ALDH1A1 P00352 3/20 0.37
▸ HTT P42858 2/20 0.37
▸ GAA P10253 1/20 0.37
▸ L3MBTL1 Q9Y468 1/20 0.37
▸ KDM4E B2RXH2 2/20 0.35
▸ SCN5A Q14524 2/20 0.34
▸ SCN9A Q15858 2/20 0.34
▸ CHRM1 P11229 1/20 0.34
▸ MEN1 O00255 1/20 0.34
▸ KMT2A Q03164 1/20 0.34
▸ RPS6KB1 P23443 2/20 0.34
▸ NPC1 O15118 1/20 0.34
▸ MAPT P10636 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8273310 0.92 GAA (0.44) ADAM17ALDH1A1HTTGAAL3MBTL1
SCHEMBL8273591 0.92 ADAM17 (0.43) ADAM17HDAC3HDAC2HDAC1ALDH1A1
SCHEMBL8273592 0.91 HTT (0.46) ADAM17ALDH1A1HTTGAAL3MBTL1
SCHEMBL8273579 0.89 CTSS (0.41) ADAM17ALDH1A1HTTGAAKDM4E
SCHEMBL8273584 0.88 NAMPT (0.37) ADAM17EIF4EMKNK1MKNK2HDAC3
SCHEMBL8213711 0.87 ADAM17 (0.49) ADAM17EIF4EMKNK1MKNK2SCN5A
SCHEMBL8273578 0.86 ADAM17 (0.39) ADAM17HDAC3HDAC2HDAC1ALDH1A1
SCHEMBL8274407 0.86 ADAM17 (0.43) ADAM17ALDH1A1HTTGAAL3MBTL1
SCHEMBL8273311 0.86 ADAM17 (0.41) ADAM17HDAC3HDAC2HDAC1ALDH1A1
SCHEMBL8276118 0.86 ADAM17 (0.43) ADAM17ALDH1A1HTTGAAL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7652020-B2 novel hydantoin derivatives to inhibit matrix metalloproteinases (MMPs), a disintegrin and metalloproteases (ADAMs) and/or tumor necrosis factor alpha converting enzyme (TACE) and in so doing prevent the release of tumor necrosis factor alpha (TNF- alpha ); autoimmune diseases; side effect reduction SCHERING CORPORATION (US) 2010-01-26 — — US disclosed
WO-2005121130-A2 CHEMICAL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM FOR THE TREATMENT OF INFLAMMATORY DISORDERS SCHERING CORPORATION (US) 2005-12-22 — — WO disclosed
Send feedback